Toxicologic Pathology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text Free
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Livraghi, A.
Right arrow Articles by Randell, S. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Livraghi, A.
Right arrow Articles by Randell, S. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Toxicologic Pathology, Vol. 35, No. 1, 116-129 (2007)
DOI: 10.1080/01926230601060025
© 2007 Society of Toxicologic Pathology

Articles

Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance

Alessandra Livraghi1 and Scott H. Randell1,2

1 Cystic Fibrosis/Pulmonary Research and Treatment Center, Department of Medicine, The University of North Carolina at Chapel Hill
2 Department of Cell and Molecular Physiology, The University of North Carolina at Chapel Hill

Correspondence: Address correspondence to: Scott H. Randell, UNC CF Center, CB 7248, Room 4011 Thurston-Bowles Building, Chapel Hill, NC 27599; e-mail:randell{at}med.unc.edu

Exposed to a diverse array of potentially noxious agents, the respiratory tract is protected by a highly developed innate defense system. Physiologically regulated epithelial ion and water transport coordinated with mucin secretion, beating cilia, and cough results in continuous flow of fluid and mucus over airway surfaces toward the larynx. This cleansing action is the initial and perhaps most quantitatively important innate defense mechanism. Repeated lung infections and eventual respiratory insufficiency characteristic of human cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) illustrate the consequences of impaired mucus clearance. Altered mucus clearance likely contributes to the initiation, progression, and chronicity of other airway diseases characterized by inflammation and mucous secretory cell hyper/metaplasia that afflict millions worldwide, including chronic obstructive pulmonary disease (COPD). This review concisely discusses the pathophysiology of human diseases characterized by genetic defects that impair mucus clearance. It then explores animal models in which components of the mucus clearance system have been disrupted. These models firmly establish the importance of mucus clearance for respiratory health, and will help elucidate disease mechanisms and therapeutic strategies in CF, PCD and COPD.

Key Words: Chronic obstructive pulmonary disease • cilia • mucin • mucociliary clearance • cystic fibrosis • primary ciliary dyskinesia

Abbreviations: CF, cystic fibrosis • PCD, primary ciliary dyskinesia • COPD, chronic obstructive pulmonary disease • PCL, peri-ciliary layer • ASL, airway surface liquid • CFTR, cystic fibrosis transmembrane conductance regulator • ENaC, epithelial sodium channel • OMIM, Online Mendelian Inheritance in Man • TEM, transmission electron microscopy • PD, potential difference • Isc, short circuit current


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
S. W. Glasser, A. P. Senft, J. A. Whitsett, M. D. Maxfield, G. F. Ross, T. R. Richardson, D. R. Prows, Y. Xu, and T. R. Korfhagen
Macrophage Dysfunction and Susceptibility to Pulmonary Pseudomonas aeruginosa Infection in Surfactant Protein C-Deficient Mice
J. Immunol., July 1, 2008; 181(1): 621 - 628.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. J. Hirsh, J. Zhang, A. Zamurs, J. Fleegle, W. R. Thelin, R. A. Caldwell, J. R. Sabater, W. M. Abraham, M. Donowitz, B. Cha, et al.
Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 77 - 88.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
A. Livraghi, M. Mall, A. M. Paradiso, R. C. Boucher, and C. M. P. Ribeiro
Modelling Dysregulated Na+ Absorption in Airway Epithelial Cells with Mucosal Nystatin Treatment
Am. J. Respir. Cell Mol. Biol., April 1, 2008; 38(4): 423 - 434.
[Abstract] [Full Text] [PDF]